US 11,833,125 B2
Pharmaceutical composition for controlled release of treprostinil
Pei Kan, Taipei (TW); Yi Fong Lin, New Taipei (TW); and Ko Chieh Chen, Taipei (TW)
Assigned to PHARMOSA BIOPHARM INC., Taipei (TW)
Filed by Pharmosa Biopharm Inc., Taipei (TW)
Filed on Oct. 27, 2021, as Appl. No. 17/511,819.
Application 17/511,819 is a division of application No. 16/404,272, filed on May 6, 2019, granted, now 11,229,616.
Claims priority of provisional application 62/670,875, filed on May 14, 2018.
Claims priority of provisional application 62/667,889, filed on May 7, 2018.
Prior Publication US 2022/0047537 A1, Feb. 17, 2022
Int. Cl. A61K 31/192 (2006.01); A61K 9/00 (2006.01); A61P 11/00 (2006.01); A61K 47/28 (2006.01); A61K 9/127 (2006.01)
CPC A61K 31/192 (2013.01) [A61K 9/0073 (2013.01); A61K 9/1272 (2013.01); A61K 47/28 (2013.01); A61P 11/00 (2018.01)] 20 Claims
OG exemplary drawing
 
1. A method of treating a respiratory disease, comprising the steps of administering a pharmaceutical composition comprising:
one or more liposome, said liposome comprising:
(a) an external lipid bilayer, comprising at least one vesicle-forming phospholipid; and
(b) an internal aqueous medium, comprising treprostinil and a salt to provide a pH gradient between the internal aqueous medium,
wherein the weight ratio of treprostinil to the at least one vesicle-forming phospholipid (T/P ratio) is equal to or higher than about 0.035 and about less than 60% of the treprostinil is released within 2 hours after the administration of the pharmaceutical composition and more than 80% of the treprostinil is released more than 2 hours to about 72 hours after the administration of the pharmaceutical composition.